knee osteoarthritis/ knee rheumatoid arthritis
Conditions
Interventions
IPACK group:infiltration of 20 ml ropivacaine 0.25% between the interspace between the popliteal artery and capsule of the knee
control group:infiltration of 20ml 0.9% salinebetween the interspace between the popliteal artery and capsule of the knee
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) The patients who had flexion deformity of knee who underwent TKA(aged over 18 years); (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) American Society of Anesthesiologists Physical Status classification I-III. (5) To be able to and willing to provide signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Contraindication to regional anesthesia or peripheral nerve blocks, allergy to local an- esthetics, allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) (2) chronic renal insufficiency (Cr > 1.4 mg/dL or glomerular filtration rate 3 months) (4) pre-existing peripheral neuropathy involving the operative site (5) body mass index >40 kg/m2. (6) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (7) Abnormal immune function or combined immune-related disease preoperatively; (8) Abnormal inflammatory index preoperatively (C-reactive protein > 20 mg/L); (9) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (10) Discontinuation of oral anticoagulants or aspirin less than 1 week; (11) Allergy to tranexamic acid (TXA) or dexamethasone or have contraindications; (12) Patients at high risk of thrombosis; (13) History of deep vein thrombosis (VTE, calf muscle vein thrombosis or superficial vein thrombosis, pulmonary embolism); (14) Serious liver and kidney dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS pain score;Morphine consumption;Time for First Analgesic Request; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quadriceps muscle strength;Walking distance;Range of motion;PONV;color Doppler Ultrasonic (CDU) examination in lower extremity;SF-12;Satisfaction scores;Sleep quality;Opioid-Related Adverse Effects;Ambulation time;KSS; | — |
Countries
China
Contacts
Public ContactZongke Zhou
West China Hospital, Sichuan University
Outcome results
None listed